Inventiva S.A. (NASDAQ:IVA - Get Free Report)'s share price rose 0.8% on Tuesday . The stock traded as high as $3.67 and last traded at $3.65. Approximately 8,903 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 64,692 shares. The stock had previously closed at $3.62.
Analyst Ratings Changes
IVA has been the topic of several recent analyst reports. Guggenheim reduced their target price on Inventiva from $12.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, April 4th. HC Wainwright restated a "buy" rating and set a $13.00 price target on shares of Inventiva in a research note on Friday, March 28th. Finally, TD Cowen initiated coverage on Inventiva in a research note on Friday, February 21st. They issued a "buy" rating and a $10.00 target price for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Inventiva has a consensus rating of "Moderate Buy" and a consensus price target of $10.40.
Read Our Latest Analysis on IVA
Inventiva Price Performance
The stock's 50-day moving average is $3.43 and its 200 day moving average is $2.87.
Institutional Investors Weigh In On Inventiva
A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
